Intravesical oxybutynin for neurogenic bladder dysfunction: Less systemic side effects due to reduced first pass metabolism

Journal of Urology

Volumn 160, Issue 3 I, 1998, Pages 892-896

  Buyse, Gunnar ^a   Waldeck, Kristian ^b   Verpoorten, Carla ^b   Björk, Henrik ^b   Casaer, Paul ^b   Andersson, Karl Erik ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b NONE

Author keywords

Bladder; Intravesical therapy; Neurogenic; Oxybutynin

Indexed keywords

DRUG METABOLITE; OXYBUTYNIN;

ADOLESCENT; ANTICHOLINERGIC EFFECT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; FEMALE; FIRST PASS EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MALE; NEUROGENIC BLADDER; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEADY STATE;

EID: 0032322568     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62828-3     Document Type: Article

References (18)

1. Bauer, S. B. and Joseph, D. B.: Management of the obstructed urinary tract associated with neurogenic bladder dysfunction. Urol. Clin. N. Am., 17: 395, 1990.
2. Fernandes, E. T., Reinberg, Y., Vernier, R. and Gonzales, R.: Neurogenic bladder dysfunction in children: review of pathophysiology and current management. J. Pediatr., 124: 1, 1994.
3. Yarker, Y. E., Goa, K. L. and Fitton, A.: Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging, 6: 243, 1995.
4. Brendler, C. B., Radebaugh, L. C. and Mohler, J. L.: Topical oxybutynin chloride for relaxation of dysfunctional bladders. J. Urol., 141: 1350, 1989.
5. Greenfield, S. P. and Fera, M.: The use of intravesical oxybutynin chloride in children with neurogenic bladders. J. Urol., 146: 532, 1991.
6. Madersbacher, H. and Jilg, G.: Control of detrusor hyperreflexia by the intravesical instillation of oxybutynin hydrochloride. Paraplegia, 29: 84, 1991.
7. Kasabian, N. G., Vlachiotis, J. D., Lais, A., Klumpp, B., Kelly, M. D., Siroky, M. B. and Bauer, S. B.: The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia. J. Urol., 151: 944, 1994.
8. Buyse, G., Verpoorten, C., Vereecken, R. and Casaer, P.: Treatment of neurogenic bladder dysfunction in infants and children with neurospinal dysraphism with clean intermittent (self) catheterisation and optimized intravesical oxybutynin hydrochloride therapy. Eur. J. Pediatr. Surg., 5 Suppl I: 31, 1995.
9. Painter, K. A., Vates, T. S., Bukowski, T. P., Fleming, P., Freedman, A. L., Smith, C. A., Gonzales, R. and Perlmutter, A. D.: Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia. J. Urol., 156: 1459, 1996.
10. Buyse, G., Verpoorten, C., Vereecken, R. and Casaer, P.: Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction. J. Urol. (in press).
11. Lindeke, B., Hallström, G., Johansson, C., Ericsson, K., Olsson, L. I. and Strömberg, S.: Metabolism of oxybutynin: establishment of desethyloxybutynin and oxybutynin N-oxide formation in rat liver preparations using deuterium substitution and gas chromatographic mass spectrometric analysis. Biomed. Mass. Spec., 8: 506, 1981.
12. Aaltonen, L., Allonen, H., Iisalo, E., Juhakoski, A., Kleimola, T. and Sellman, R.: Antimuscarinic activity of oxybutynin in the human plasma quantitated by a radioreceptor assay. Acta Pharmacol. Toxicol., 55: 100, 1984.
13. Hughes, K. M., Lang, J. C. T., Lazare, R., Gordon, D., Stanton, S. L., Malone-Lee, J. and Geraint, M.: Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica, 22: 859, 1992.
14. Waldeck, K., Larsson, B. and Andersson, K. E.: Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J. Urol., 157: 1093, 1997.
15. Massad, C. A., Kogan, B. A. and Trigo-Rocha, F. E.: The pharmacokinetics of intravesical and oral oxybutynin chloride. J. Urol., 148: 595, 1992.
16. Madersbacher, H. and Knoll, M.: Intravesical application of oxybutynin: Mode of action in controlling detrusor hyperreflexia. Eur. Urol., 28: 340, 1995.
17. Douchamps, J., Derenne, F., Stockis, A., Gangji, D., Juvent, M. and Herchuelz, A.: The pharmacokinetics of oxybutynin in man. Eur. J. Clin. Pharmacol., 35: 515, 1988.
18. Mohler, J. L.: Relaxation of intestinal bladders by intravesical oxybutynin chloride. Neurourol. Urodynam., 9: 179, 1990.